Form 4: Vertex Pharmaceuticals Director Acquires Deferred Stock Units

Director Suketu Upadhyay acquired deferred stock units convertible to common stock in Vertex Pharmaceuticals.

Summary

• On April 15, 2025, Suketu Upadhyay, a director of Vertex Pharmaceuticals, acquired 71.607 deferred stock units.
• Each deferred stock unit represents one share of Vertex Pharmaceuticals common stock.
• These units will be paid out in common stock upon the earliest of Mr. Upadhyay's board service termination, a change of control of the company, or Mr. Upadhyay's disability or death.
• Following the transaction, Mr. Upadhyay directly owns 1,474.603 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, suggesting stability and alignment of interests between the director and the company. It's a neutral positive.

Positives

• The acquisition of deferred stock units by a director signals confidence in the company's future.

Future Outlook

The deferred stock units will convert to common stock upon the occurrence of specific events in the future.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Comparison to Industry Standards

• Director stock ownership is a common practice across the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also have similar stock ownership guidelines for their directors.
• The amount of stock held by directors varies based on company size, tenure, and individual investment strategies.

Stakeholder Impact

• The transaction could positively influence shareholder confidence due to the director's increased stake in the company.

Key Dates

Keywords

Vertex Pharmaceuticals, Director, Suketu Upadhyay, Deferred Stock Units, Common Stock, Beneficial Ownership, Form 4